Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:694023.
doi: 10.1155/2015/694023. Epub 2015 Oct 20.

Lithium Carbonate in the Treatment of Graves' Disease with ATD-Induced Hepatic Injury or Leukopenia

Rendong Zheng  1 , Kemian Liu  1 , Kun Chen  1 , Wen Cao  1 , Lin Cao  1 , Huifeng Zhang  1 , Hongping Sun  1 , Chao Liu  1
Affiliations

Lithium Carbonate in the Treatment of Graves' Disease with ATD-Induced Hepatic Injury or Leukopenia

Rendong Zheng et al. Int J Endocrinol. 2015.

Abstract

Objective. GD with ATD-induced hepatic injury or leukopenia occurs frequently in clinical practice. The purpose of the present study was to observe the clinical effect of lithium carbonate on hyperthyroidism in patients with GD with hepatic injury or leukopenia. Methods. Fifty-one patients with GD with hepatic injury or leukopenia participated in the study. All patients were treated with lithium carbonate, in addition to hepatoprotective drugs or drugs that increase white blood cell count. Thyroid function, liver function, and white blood cells were measured. Clinical outcomes were observed after a 1-year follow-up. Results. After treatment for 36 weeks, symptoms of hyperthyroidism and the level of thyroid hormones were improved and liver function, and white blood cells returned to a normal level. Twelve patients (23.5%) obtained clinical remission, 6 patients (11.8%) relapsed after withdrawal, 25 patients (49.0%) received radioiodine therapy, and 8 patients (15.7%) underwent surgical procedures after lithium carbonate treatment. Conclusion. Lithium carbonate has effects on the treatment of mild-to-moderate hyperthyroidism caused by GD, and it is particularly suitable for patients with ATD-induced hepatic injury or leukopenia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Outcome of serum thyroid hormone concentrations. Outcome of serums FT3, FT4, and TSH concentrations in GD with hepatic injury treated with lithium are shown by black line and that in GD with leukopenia treated with lithium is shown by gray line. Difference in the outcome of serums FT3, FT4, and TSH concentrations between baseline and lithium treatment versus baseline; ∗ p < 0.05; ∗∗ p < 0.01.
Figure 2
Figure 2
Clinical outcome. The number of patients with different outcomes in GD with hepatic injury (black) and in GD with leukopenia (gray).
See this image and copyright information in PMC

References

    1. Brent G. A. Clinical practice. Graves' disease. The New England Journal of Medicine. 2008;358(24):2594–2605. doi: 10.1056/nejmcp0801880. - DOI - PubMed
    1. Williams K. V., Nayak S., Becker D., Reyes J., Burmeister L. A. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? The Journal of Clinical Endocrinology and Metabolism. 1997;82(6):1727–1733. - PubMed
    1. Liaw Y.-F., Huang M.-J., Fan K.-D., Li K.-L., Wu S.-S., Chen T.-J. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Annals of Internal Medicine. 1993;118(6):424–428. doi: 10.7326/0003-4819-118-6-199303150-00005. - DOI - PubMed
    1. Woeber K. A. Methimazole-induced hepatotoxicity. Endocrine Practice. 2002;8(3):222–224. doi: 10.4158/ep.8.3.222. - DOI - PubMed
    1. Cooper D. S. Antithyroid drugs. The New England Journal of Medicine. 2005;352(9):905–917. doi: 10.1056/nejmra042972. - DOI - PubMed

LinkOut - more resources